Cephalon executives to join Arana board
This article was originally published in Scrip
Four senior Cephalon executives have joined the board of Arana Therapeutics, following Cephalon's acquisition of a majority holding in the Australian antibody firm. They are chairman and CEO Dr Frank Baldino Jr, chief financial officer Kevin Buchi, chief scientific officer Dr Jeffry Vaught and chief medical officer Dr Lesley Russell. Dr Baldino has been appointed chairman to succeed Robin Beaumont, who will step down to become lead independent director. Gordon Black and Lincoln Chee have retired as non-independent directors from Arana's board.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.